Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trial.
A double-blind placebo-controlled trial of 7 days administration of lamotrigine as add-on therapy was performed in 10 patients with frequent therapy-resistant, chiefly partial, seizures. Dosage was adjusted on the basis of estimated half-life. Six patients showed a 50% seizure reduction on lamotrigine and two an increase. Side effects (ataxia, dizziness and apathy) occurred in 3 patients, but only at blood levels above 3 micrograms/ml, and were rapidly relieved when the dose was reduced in two. EEG spike counts were significantly reduced on lamotrigine. There was no evidence of interactions with co-medication.
Binnie
C D
CD
Wellcome Research Laboratories, Beckenham, Kent, U.K.
Beintema
D J
DJ
Debets
R M
RM
Van Emde Boas
W
W
Meijer
J W
JW
Meinardi
H
H
Peck
A W
AW
Westendorp
A M
AM
Yuen
W C
WC
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077213:Lamotrigine; D008875:Middle Aged; D010919:Placebos; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014227:Triazines; D000077213:Lamotrigine